RUNX3 and plasma cell myeloma: In conclusion, the PRS of the selected genetic variants for DU risk was mainly associated with actin modification, LRR domain binding, Shaffer IRF4 targets in myeloma vs. mature B lymphocytes, and Reactome runx3 regulated immune response and cell migration.